NASDAQ · Financial Statements

Castle Biosciences, Inc. (CSTL) Financial Statements

$33.08 NASDAQ: CSTL Market Cap $1.01B

Castle Biosciences, Inc. most recently reported annual revenue of $344.0M, a net loss of $24.0M. Revenue grew at an average annual rate of 40.4% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Castle Biosciences, Inc.: Revenue rose from $14.0M in 2017 to $344.0M in 2025, a change of +2357.1% over 8 years; net profit was positive in 2 of 9 reported years; operating margin moved from -79.3% to -12.4%, a shift of +66.8 percentage points; the most recent year shows a net loss of $24.0M.

Income Statement — 9 Years (USD millions)

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	$14.0M	$23.0M	$52.0M	$63.0M	$94.0M	$137.0M	$220.0M	$332.0M	$344.0M
Operating Expenses	$25.0M	$27.0M	$45.0M	$69.0M	$134.0M	$210.0M	$288.0M	$323.0M	$387.0M
Operating Profit	$-11.0M	$-4.0M	$7.0M	$-7.0M	$-40.0M	$-73.0M	$-68.0M	$9.0M	$-43.0M
Operating Margin	-79.3%	-16.8%	14.1%	-10.4%	-42.6%	-53.2%	-30.9%	2.6%	-12.4%
Other Income	$-1.0M	$-3.0M	$-2.0M	$-4.0M	$0	$4.0M	$11.0M	$13.0M	$13.0M
Interest	$2.0M	$2.0M	$5.0M	$3.0M	$0	$0	$0	$1.0M	$0
Depreciation	$0	$0	$0	$0	$3.0M	$11.0M	$12.0M	$16.0M	$41.0M
Profit Before Tax	$-12.0M	$-6.0M	$5.0M	$-10.0M	$-40.0M	$-69.0M	$-57.0M	$22.0M	$-30.0M
Tax	$-80,000	$-140,000	$1.4M	$-820,000	$21.8M	$2.6M	$-180,000	$15.4M	$18.1M
Net Profit	$-12.0M	$-6.0M	$5.0M	$-10.0M	$-31.0M	$-67.0M	$-57.0M	$18.0M	$-24.0M
EPS	$-1.26	$-0.60	$-0.21	$-0.54	$-1.24	$-2.58	$-2.14	$0.62	$-0.83
Dividend Payout	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

Metric	Sep '23	Dec '23	Mar '24	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26
Revenue	$61.0M	$66.0M	$73.0M	$87.0M	$86.0M	$86.0M	$88.0M	$86.0M	$83.0M	$87.0M	$84.0M	$104.0M
Operating Expenses	$71.0M	$72.0M	$78.0M	$82.0M	$81.0M	$82.0M	$116.0M	$90.0M	$90.0M	$91.0M	$102.0M	$107.0M
Operating Profit	$-10.0M	$-6.0M	$-5.0M	$5.0M	$5.0M	$4.0M	$-28.0M	$-4.0M	$-7.0M	$-4.0M	$-18.0M	$-3.0M
Operating Margin	-15.7%	-8.6%	-7.5%	5.8%	5.9%	4.7%	-31.7%	-4.9%	-8.2%	-4.4%	-22.0%	-3.0%
Interest	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Profit Before Tax	$-7.0M	$-3.0M	$-2.0M	$8.0M	$8.0M	$8.0M	$-26.0M	$0	$0	$-3.0M	$-14.0M	$-2.0M
Tax	$-470,000	$-1.5M	$-1.8M	$-13.1M	$72.6M	$-21.6M	$1.6M	$3.3B	$-29.8M	$14.1M	$-760,000	$-21.9M
Net Profit	$-7.0M	$-3.0M	$-3.0M	$9.0M	$2.0M	$10.0M	$-26.0M	$5.0M	$-1.0M	$-2.0M	$-15.0M	$-2.0M
EPS	$-0.26	$-0.10	$-0.09	$0.31	$0.08	$0.32	$-0.90	$0.15	$-0.02	$-0.08	$-0.49	$-0.07

Over the 9 years reported for Castle Biosciences, Inc., borrowings increased from $19.0M in 2017 to $37.0M in 2025, cash stood at $117.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 5.23 times.

Balance Sheet — 9 Years (USD millions)

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Total Assets	$10.0M	$22.0M	$120.0M	$439.0M	$463.0M	$447.0M	$453.0M	$531.0M	$579.0M
Current Assets	$7.0M	$18.0M	$117.0M	$430.0M	$354.0M	$292.0M	$296.0M	$360.0M	$361.0M
Cash	$1.0M	$4.0M	$99.0M	$410.0M	$330.0M	$123.0M	$99.0M	$120.0M	$117.0M
Inventory	$0	$1.0M	$1.0M	$2.0M	$2.0M	$4.0M	$8.0M	$8.0M	$10.0M
Receivables	$5.0M	$12.0M	$15.0M	$13.0M	$17.0M	$23.0M	$38.0M	$51.0M	$43.0M
Fixed Assets	$1.0M	$2.0M	$2.0M	$7.0M	$17.0M	$26.0M	$38.0M	$63.0M	$112.0M
Capital Work in Progress	$0	$0	$0	$0	$0	$0	$0	$0	$0
Investments	$2.0M	$3.0M	$0	$0	$1.0M	$136.0M	$144.0M	$173.0M	$183.0M
Other Assets	$0	$0	$0	$0	$0	$11.0M	$11.0M	$11.0M	$11.0M
Total Liabilities	$24.0M	$32.0M	$35.0M	$24.0M	$51.0M	$48.0M	$62.0M	$75.0M	$108.0M
Current Liabilities	$5.0M	$7.0M	$15.0M	$21.0M	$25.0M	$36.0M	$48.0M	$49.0M	$69.0M
Borrowings	$19.0M	$24.0M	$25.0M	$0	$8.0M	$13.0M	$15.0M	$26.0M	$37.0M
Other Liabilities	$5.0M	$8.0M	$10.0M	$24.0M	$43.0M	$35.0M	$47.0M	$49.0M	$71.0M
Equity	$0	$0	$0	$0	$0	$0	$0	$0	$0
Reserves	$-14.0M	$-10.0M	$85.0M	$416.0M	$412.0M	$399.0M	$391.0M	$456.0M	$471.0M

For Castle Biosciences, Inc., operating cash flow was positive in 4 of 9 reported years; free cash flow in the latest year was $28.0M; free cash flow was positive in 4 of 9 years; financing activities used $9.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 9 Years (USD millions)

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating Cash Flow	$-12.0M	$-12.0M	$7.0M	$10.0M	$-19.0M	$-42.0M	$-6.0M	$65.0M	$64.0M
Investing Cash Flow	$-1.0M	$-1.0M	$-2.0M	$-9.0M	$-70.0M	$-172.0M	$-30.0M	$-78.0M	$-96.0M
Financing Cash Flow	$0	$0	$1.0M	$3.0M	$5.0M	$2.0M	$-2.0M	$-6.0M	$-9.0M
Net Cash Flow	$-4.0M	$3.0M	$94.0M	$311.0M	$-80.0M	$-207.0M	$-24.0M	$21.0M	$-3.0M
Free Cash Flow	$-13.0M	$-13.0M	$6.0M	$5.0M	$-22.0M	$-47.0M	$-19.0M	$37.0M	$28.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.54
EV / EBITDA	-327.84
FCF Yield	-0.05%
Quick Ratio	5.85
Interest Coverage	-85.62
Return 1Y	51.67%
Return 3Y	60.86%
Return 5Y	-64.40%

Castle Biosciences, Inc. (CSTL) financials — frequently asked questions

What is Castle Biosciences, Inc.'s annual revenue?

Castle Biosciences, Inc. (CSTL) reported annual revenue of $344.0M in its most recent fiscal year.

What is Castle Biosciences, Inc.'s net profit?

Castle Biosciences, Inc. (CSTL) reported a net loss of $24.0M in its most recent fiscal year.

What is CSTL EV/EBITDA?

Castle Biosciences, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -327.84. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Related stock screens

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks High ROE Stocks Low P/E Stocks High Net Margin Stocks Dividend Stocks Low Debt Stocks Nasdaq High ROE Stocks All stock screens

CSTL Overview CSTL Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.